Robert B. Kay
Executive Chairman and Chief Executive Officer
Robert B. Kay is our Executive Chairman and Chief Executive Officer and has served in these capacities since we became a publicly traded company in August 2008. Previously, Mr. Kay was a founder and senior partner of the New York law firm of Kay Collyer & Boose LLP, with a particular focus on mergers and acquisitions and joint ventures. Mr. Kay received his B.A. from Cornell University's College of Arts & Sciences and his J.D. from New York University Law School. Mr. Kay oversees every aspect of our business in his role as executive chairman and chief executive officer. Given his years with the company and his prior experience, we believe that Mr. Kay has an excellent understanding of our business and the global markets in which we operate and those in which we anticipate operating in the future.
Robert L. Erwin
Robert L. Erwin previously led Large Scale Biology Corporation from its founding in 1988 through 2003, including a successful initial public offering in 2000, and continued as non-executive Chairman until 2006. Mr. Erwin recently served as Managing Director of Bio-Strategic Directors LLC providing consulting services to the life sciences industry. He served as Chairman of Icon Genetics AG from 1999 until its acquisition by a subsidiary of Bayer AG in 2006. He is currently Chairman of Novici Biotech, a private biotechnology company and a Director of Resolve Therapeutics LLC. Mr. Erwin's non-profit work focuses on applying scientific advances to clinical medicine, especially in the field of oncology. He is co-founder and President of the Marti Nelson Cancer Foundation, and a member of the Cancer Policy Forum of the Institute of Medicine. Mr. Erwin received his B.S. degree with Honors in Zoology and an M.S. degree in Genetics from Louisiana State University.
Terence E. Ryan, Ph.D.
Chief Scientific Officer
Terence E. Ryan, Ph.D. is a pharmaceutical and biotech research leader who is highly accomplished in recombinant protein expression, and also has a record of innovation in cell biology, proteomics, and systems biology. His distinguished 20-year career includes working for such industry leaders as Wyeth (Pfizer) Research, GlaxoSmithKline, Celera Genomics, and Regeneron Pharmaceuticals. Dr. Ryan holds an M.S. and Ph.D. in Microbiology from Rutgers University, and received his AB in Biology from Princeton University.
Douglas C. Hicks
Senior Vice President, Business Development & Strategy
Douglas C. Hicks is the Senior Vice-President, Business Development & Strategy for iBio, Inc. Mr. Hicks has nearly twenty years of operational, financial, and administrative experience within both small and large businesses. He has primarily focused on business development, corporate planning, and strategy execution within the biotechnology, pharmaceutical, and private equity segments. Prior to joining iBio in 2010, Mr. Hicks was with Clearview Projects, Inc., a strategic advisory firm which provides business development, product alliance, and strategic advice to the pharmaceutical and biotechnology industry. Mr. Hicks joined Clearview when the firm was formed in 2001 and has held various roles of increased responsibility over his 10 year tenure with the firm, most recently as Executive Director of Business Development and Strategic Analysis. While at Clearview, he participated in over thirty-five strategic transactions across various therapeutic areas. Before joining Clearview, Mr. Hicks was a consultant at Bristol-Myers Squibb. Mr. Hicks received his MBA from The Pennsylvania State University, with a focus on finance and strategy.
James P. Mullaney
Chief Financial Officer
James P. Mullaney has over 20 years of experience encompassing finance, accounting, management and advisory positions. He has been a member of PwC's Audit practice as well as KPMG's CFO Advisory Services practice. Prior to joining iBio, Inc., Mr. Mullaney served in the capacity as Corporate Controller for Citihub Consulting, a multi-national IT services firm. He brings extensive finance transformation, strategic development and partnership, internal control and regulatory compliance background to iBio, Inc. He holds a CPA license in New York State.
Wayne P. Fitzmaurice, Ph.D.
Vice President, Intellectual Property
Wayne P. Fitzmaurice, PhD. has extensive experience in plant biotechnology research, and is a USPTO certified Patent Agent. He led research teams at Biosource Technologies (later Large Scale Biology Corp.) for 15 years from 1992 to 2007 ultimately holding the position of Senior Director of Plant Biology and Pharmaceutical Development. He is a founding partner of Novici Biotech, and functions as their Senior Director of Intellectual Property. With Novici he is on key patents as both an inventor and a prosecuting patent agent. He also acted as an independent consultant in biotechnology intellectual property for several corporations. Dr. Fitzmaurice received a Ph.D. in Biochemistry from The Johns Hopkins University, and did postdoctoral research at the University of Wisconsin-Madison and North Carolina State University.